Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

International Journal of Antimicrobial Agents

Volumn 56, Issue 1, 2020, Pages

  Gautret, Philippe ^a,b   Lagier, Jean Christophe ^a,c   Parola, Philippe ^a,b   Hoang, Van Thuan ^a,b,d   Meddeb, Line ^a   Mailhe, Morgane ^a   Doudier, Barbara ^a   Courjon, Johan ^e,f,g   Giordanengo, Valérie ^h   Vieira, Vera Esteves ^a   Tissot Dupont, Hervé ^a,c   Honoré, Stéphane ^b,i   Colson, Philippe ^a,c   Chabrière, Eric ^a,c   La Scola, Bernard ^a,c   Rolain, Jean Marc ^a,c   Brouqui, Philippe ^a,c   Raoult, Didier ^a,c  

^a IHU MÉDITERRANÉE INFECTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Institut Hospitalo Universitaire   (France)

^d Thai Binh University of Pharmacy and Medicine   (Viet Nam)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

^g CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ TIMONE HOSPITAL   (France)

Author keywords

2019 nCoV; Azithromycin; Clinical trial; COVID 19; Hydroxychloroquine; SARS CoV 2

Indexed keywords

AZITHROMYCIN; HYDROXYCHLOROQUINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DEMOGRAPHY; FEMALE; HUMAN; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE; THROAT CULTURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; BETACORONAVIRUS; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; MIDDLE AGED; PANDEMIC; POLYMERASE CHAIN REACTION; VIRUS PNEUMONIA;

ADULT; AZITHROMYCIN; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 85088375128     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2020.105949     Document Type: Article

References (23)

1. Lai, C.C., Shih, T.P., Ko, W.C., Tang, H.J., Hsueh, P.R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents, 2020 Feb 17, 105924, 10.1016/j.ijantimicag.2020.105924 [Epub ahead of print].
2. Wang, L.S., Wang, Y.R., Ye, D.W., Liu, Q.Q., A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence”. Int J Antimicrob Agents, 2020 [Epub ahead of print].
3. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [ https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020].
4. Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020 Feb 24, 10.1001/jama.2020.2648 [Epub ahead of print].
5. Santé Publique France. Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde [ https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-monde].
6. Colson, P., Rolain, J.M., Raoult, D., Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents, 2020 Feb 15, 105923, 10.1016/j.ijantimicag.2020.105923 [Epub ahead of print].
7. Colson, P., Rolain, J.M., Lagier, J.C., Brouqui, P., Raoult, D., Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents, 2020 [Epub ahead of print].
8. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 10–0282.
9. Gao, J., Tian, Z., Yang, X., Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 2020 Feb 19, 10.5582/bst.2020.01047 [Epub ahead of print].
10. Chinese Clinical Trial Registry. http://www.chictr.org.cn/searchproj.aspx?title=%E6%B0%AF%E5%96%B9&officialname=&subjectid=&secondaryid=&applier=&studyleader=ðicalcommitteesanction=&sponsor=&studyailment=&studyailmentcode=&studytype=0&studystage=0&studydesign=0&minstudyexecutetime=&maxstudyexecutetime=&recruitmentstatus=0&gender=0&agreetosign=&secsponsor=®no=®status=0&country=&province=&city=&institution=&institutionlevel=&measure=&intercode=&sourceofspends=&createyear=0&isuploadrf=&whetherpublic=&btngo=btn&verifycode=&page=1.
11. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 43:3 (2020 Mar 12), 185–188, 10.3760/cma.j.issn.1001-0939.2020.03.009.
12. Biot, C., Daher, W., Chavain, N., Fandeur, T., Khalife, J., Dive, D., et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 49 (2006), 2845–2849.
13. Marmor, M.F., Kellner, U., Lai, T.Y., Melles, R.B., Mieler, W.F., American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 123:6 (Jun 2016), 1386–1394, 10.1016/j.ophtha.2016.01.058 Epub 2016 Mar 16.
14. Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2020 Mar 9, 10.1093/cid/ciaa237 pii: ciaa237[Epub ahead of print].
15. Raoult, D., Houpikian, P., Tissot Dupont, H., Riss, J.M., Arditi-Djiane, J., Brouqui, P., Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 159:2 (1999 Jan 25), 167–173.
16. Lagier, J.C., Raoult, D., Whipple's disease and Tropheryma whipplei infections: when to suspect them and how to diagnose and treat them. Curr Opin Infect Dis 31:6 (Dec 2018), 463–470, 10.1097/QCO.0000000000000489 [x] Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
17. Amrane, S., Tissot-Dupont, H., Doudier, B., Eldin, C., Hocquart, M., Mailhe, M., et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot. Travel Med Infect Dis, 2020 [Epub ahead of print].
18. Armstrong, N., Richez, M., Raoult, D., Chabriere, E., Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1060 (2017), 166–172.
19. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020 Mar 11, 10.1016/S0140-6736(20)30566-3 pii: S0140-6736(20)30566-3[Epub ahead of print].
20. Retallack, H., Di Lullo, E., Arias, C., Knopp, K.A., Laurie, M.T., Sandoval-Espinosa, C., et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A 113:50 (2016 Dec 13), 14408–14413 Epub 2016 Nov 29.
21. Madrid, P.B., Panchal, R.G., Warren, T.K., Shurtleff, A.C., Endsley, A.N., Green, C.E., Kolokoltsov, A., et al. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect Dis 1:7 (2015 Jul 10), 317–326, 10.1021/acsinfecdis.5b00030 Epub 2015 May 11.
22. Bosseboeuf, E., Aubry, M., Nhan, T., de Pina, J.J., Rolain, J.M., Raoult, D., et al. Azithromycin inhibits the replication of Zika virus. J Antivirals Antiretrovirals 10:1 (2018), 6–11, 10.4172/1948-5964.1000173.
23. Bacharier, L.B., Guilbert, T.W., Mauger, D.T., Boehmer, S., Beigelman, A., Fitzpatrick, A.M., et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial. JAMA 314:19 (2015 Nov 17), 2034–2044, 10.1001/jama.2015.13896.